CL2017000402A1 - Anticuerpos anti-vasa y métodos de producción y uso de los mismos - Google Patents

Anticuerpos anti-vasa y métodos de producción y uso de los mismos

Info

Publication number
CL2017000402A1
CL2017000402A1 CL2017000402A CL2017000402A CL2017000402A1 CL 2017000402 A1 CL2017000402 A1 CL 2017000402A1 CL 2017000402 A CL2017000402 A CL 2017000402A CL 2017000402 A CL2017000402 A CL 2017000402A CL 2017000402 A1 CL2017000402 A1 CL 2017000402A1
Authority
CL
Chile
Prior art keywords
mabs
methods
vase
cdrs
production
Prior art date
Application number
CL2017000402A
Other languages
English (en)
Spanish (es)
Inventor
David T Weaver
Bo Zhang
Original Assignee
Ovascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovascience Inc filed Critical Ovascience Inc
Publication of CL2017000402A1 publication Critical patent/CL2017000402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CL2017000402A 2014-09-16 2017-02-17 Anticuerpos anti-vasa y métodos de producción y uso de los mismos CL2017000402A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US201462089054P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
CL2017000402A1 true CL2017000402A1 (es) 2017-11-03

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000402A CL2017000402A1 (es) 2014-09-16 2017-02-17 Anticuerpos anti-vasa y métodos de producción y uso de los mismos

Country Status (26)

Country Link
US (4) US9403913B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194448A4 (cg-RX-API-DMAC7.html)
JP (2) JP2017532953A (cg-RX-API-DMAC7.html)
KR (1) KR20170056521A (cg-RX-API-DMAC7.html)
CN (1) CN106573985A (cg-RX-API-DMAC7.html)
AP (1) AP2017009758A0 (cg-RX-API-DMAC7.html)
AU (1) AU2015317813B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017003263A2 (cg-RX-API-DMAC7.html)
CA (1) CA2959179A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017000402A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017001724A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170067A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000050A (cg-RX-API-DMAC7.html)
EA (1) EA201790236A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17011262A (cg-RX-API-DMAC7.html)
GT (1) GT201700036A (cg-RX-API-DMAC7.html)
IL (1) IL250451A0 (cg-RX-API-DMAC7.html)
MX (1) MX358243B (cg-RX-API-DMAC7.html)
NI (1) NI201700022A (cg-RX-API-DMAC7.html)
PE (1) PE20170667A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500309A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701016WA (cg-RX-API-DMAC7.html)
SV (1) SV2017005393A (cg-RX-API-DMAC7.html)
TN (1) TN2017000066A1 (cg-RX-API-DMAC7.html)
TW (1) TW201619194A (cg-RX-API-DMAC7.html)
WO (1) WO2016044436A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
TN2017000066A1 (en) * 2014-09-16 2018-07-04 Ovascience Inc Anti-vasa antibodies, and methods of production and use thereof.
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
WO2021096829A1 (en) * 2019-11-11 2021-05-20 Vanderbilt University Human monoclonal antibodies to hantavirus and methods of use therefor
CN120405134A (zh) * 2024-01-30 2025-08-01 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
EP1233978A4 (en) * 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGOSIS AND TREATMENT OF Germ Cell Tumors
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
WO2005113752A2 (en) 2004-05-17 2005-12-01 The General Hospital Corporation Methods and compositions for producing germ cells from peripheral blood derived germline stem cells
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
AU2005256113B2 (en) * 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
KR20110055687A (ko) 2008-09-25 2011-05-25 고쿠리츠 다이가쿠 호우징 도쿄 가이요우 다이가쿠 항참치 Vasa 항체
CA2748990A1 (en) * 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
NZ706806A (en) 2011-04-14 2016-12-23 Gen Hospital Corp Compositions and methods for autologous germline mitochondrial energy transfer
EP2726601B1 (en) * 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US9428575B2 (en) * 2012-12-31 2016-08-30 Development Center For Biotechnology Anti-granulysin antibodies and methods of use thereof
TN2017000066A1 (en) * 2014-09-16 2018-07-04 Ovascience Inc Anti-vasa antibodies, and methods of production and use thereof.
EP3245287A4 (en) * 2015-01-13 2018-06-20 President and Fellows of Harvard College Purification of germ stem cells by targeting mrp9

Also Published As

Publication number Publication date
CO2017001724A2 (es) 2017-07-19
PH12017500309A1 (en) 2017-07-10
TW201619194A (zh) 2016-06-01
JP2017532953A (ja) 2017-11-09
US9567404B2 (en) 2017-02-14
DOP2017000050A (es) 2018-04-15
NI201700022A (es) 2017-05-04
WO2016044436A3 (en) 2016-06-09
SV2017005393A (es) 2017-06-07
GT201700036A (es) 2018-12-19
CN106573985A (zh) 2017-04-19
BR112017003263A2 (pt) 2017-11-28
AU2015317813B2 (en) 2018-04-05
AP2017009758A0 (en) 2017-02-28
EP3194448A4 (en) 2018-03-14
TN2017000066A1 (en) 2018-07-04
US20180155445A1 (en) 2018-06-07
SG11201701016WA (en) 2017-03-30
IL250451A0 (en) 2017-03-30
EA201790236A1 (ru) 2017-11-30
US9403913B2 (en) 2016-08-02
PE20170667A1 (es) 2017-06-06
EP3194448A2 (en) 2017-07-26
MX2017002390A (es) 2017-07-28
KR20170056521A (ko) 2017-05-23
AU2015317813A1 (en) 2017-03-02
CA2959179A1 (en) 2016-03-24
WO2016044436A2 (en) 2016-03-24
ECSP17011262A (es) 2017-05-31
US20160075797A1 (en) 2016-03-17
MX358243B (es) 2018-08-10
CR20170067A (es) 2017-05-10
US20160311929A1 (en) 2016-10-27
US20170107299A1 (en) 2017-04-20
JP2018148915A (ja) 2018-09-27

Similar Documents

Publication Publication Date Title
GT201700036A (es) Anticuerpos anti-vasa y métodos de producción y uso de los mismos
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2017007826A (es) Proteina de fusion que conprende tres dominios de union a 5t4 y cd3.
UY40672A (es) “ANTICUERPOS AISLADOS BIESPECÍFICOS GPRC5D x CD3 Y COMPOSICIONES QUÍMICAS QUE LOS CONTIENEN”
MX2019013117A (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
MX2016016883A (es) Anticuerpo anti-axl.
MX384418B (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
MX375524B (es) Anticuerpos anti-axl.
MX384419B (es) Constructos de anticuerpos para cdh19 y cd3
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MX389703B (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
EP3292198A4 (en) Reversion of primed pluripotent stem cells to naive pluripotent stem cells
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
BR112015000982B8 (pt) Método para a obtenção de uma molécula de ácido nucleico sintético
EP3140392C0 (en) PRODUCTION OF HETEROMULTIMERE PROTEINS BY MAMMALIAN CELLS
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra
CO2018010286A2 (es) Método para la purificación de proteínas
MX384534B (es) Metodos de produccion de proteinas de cadena doble en bacterias.
CO2017006157A2 (es) Método de manufactura de proteína
EA201692057A1 (ru) Композиции и способы повышения производства